
CRL Stock Forecast & Price Target
CRL Analyst Ratings
Bulls say
Charles River is setting positive targets for growth, margin improvement, and cost savings through 2030, but faces risks associated with the contract research industry. The company has raised its EPS estimate and price target for 2027, with potential for further growth through strategic initiatives. However, potential risks include changes in government regulations and failure to create value through their strategic review.
Bears say
Charles River is a leading provider of drug discovery and development services, but the company's heavy reliance on animal testing for its research and development processes presents ethical and regulatory risks. Additionally, the company's limited capabilities in non-animal testing methods could lead to revenue erosion if the FDA accepts these methods faster than expected. Furthermore, there are gaps in sustainability integration, such as lack of disclosure on executive compensation tied to sustainability KPIs and limited progress in reducing animal use despite ethical concerns. As of year-end 2025, Charles River's Board of Directors has a high level of diversity, but there are concerns over transparency in animal welfare metrics and progress.
This aggregate rating is based on analysts' research of Charles River Laboratories and is not a guaranteed prediction by Public.com or investment advice.
CRL Analyst Forecast & Price Prediction
Start investing in CRL
Order type
Buy in
Order amount
Est. shares
0 shares